title: Immunization with recombinant vaccinia viruses expressing structural and part of the nonstructural region of tick-borne encephalitis virus cDNA protect mice against lethal encephalitis.
abstract: Three recombinant vaccinia viruses containing different fragments of tick-borne encephalitis virus (TBEV) cDNA representing the 5'-noncoding region (5'NCR), all structural and part of the nonstructural regions were constructed. Western blot analysis showed that E and NS1 proteins were expressed and processed correctly in cells infected with recombinant viruses vC-NS1 (coding for C-prM-E-NS1 region) and vC-NS3 (coding for C-prM-E-NS1-NS2A-NS2B-NS3 region). In contrast, in cells infected with recombinant virus v5'C-NS2A (coding for 5'NCR and C-prM-E-NS1-NS2A regions) expression of NS1 protein was greatly reduced and no E protein was detected. Immunization of mice with vC-NS3 induced high levels of TBEV-specific antibodies and protected them against intraperitoneal challenge with 10(7) LD50 of TBEV. The level of protection was very similar to the level of protection achieved by immunization with commercially available inactivated TBEV vaccine. Although the immunization of mice with recombinants vC-NS1 and v5'C-NS2A induced much lower levels of TBEV-specific antibodies, they were still protected against intraperitoneal challenge with 10(4) and 10(3.6) LD50 of TBEV, respectively. The high level of protection against TBEV infection achieved by the immunization of mice with the recombinant vaccinia virus vC-NS3 makes this virus a very attractive candidate for development of a live recombinant vaccine against TBEV.
authors.affiliation: Research Institute of Molecular Biology, State Research Center of Virology and Biotechnology Vector, Novosibirsk region, Russia.
authors.forename: I P
authors.initials: IP
authors.lastname: Dmitriev
authors.forename: A A
authors.initials: AA
authors.lastname: Khromykh
authors.forename: G M
authors.initials: GM
authors.lastname: Ignatyev
authors.forename: M N
authors.initials: MN
authors.lastname: Gainullina
authors.forename: V A
authors.initials: VA
authors.lastname: Ageenko
authors.forename: S A
authors.initials: SA
authors.lastname: Dryga
authors.forename: M S
authors.initials: MS
authors.lastname: Vorobyeva
authors.forename: L S
authors.initials: LS
authors.lastname: Sandakhchiev
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis / Q000097:blood; D000917:Antibody Formation; D001483:Base Sequence; D015153:Blotting, Western; D002213:Capsid / Q000096:biosynthesis / Q000276:immunology*; D002460:Cell Line; D002522:Chlorocebus aethiops; D018076:DNA, Complementary; D004669:Encephalitis Viruses, Tick-Borne / Q000235:genetics / Q000276:immunology*; D004675:Encephalitis, Tick-Borne / Q000276:immunology / Q000517:prevention & control*; D007114:Immunization; D007668:Kidney; D051379:Mice; D008807:Mice, Inbred BALB C; D008969:Molecular Sequence Data; D014614:Vaccines, Synthetic; D014616:Vaccinia virus; D014758:Viral Core Proteins / Q000096:biosynthesis / Q000276:immunology*; D014765:Viral Vaccines
chemical_list: D000914:Antibodies, Viral; D018076:DNA, Complementary; D014614:Vaccines, Synthetic; D014758:Viral Core Proteins; D014765:Viral Vaccines